7 news items
HC Wainwright & Co. Maintains Buy on Cassava Sciences, Raises Price Target to $131
SAVA
17 May 24
HC Wainwright & Co. analyst Vernon Bernardino maintains Cassava Sciences (NASDAQ:SAVA) with a Buy and raises the price target from $124 to $131.
Cassava Sciences Reports Clinical Updates On Phase 3 Trials Of Simufilam
SAVA
10 May 24
.The target study population is people with mild-to-moderate Alzheimer's (MMSE score of 16-27) who are biomarker-positive for Alzheimer's disease pathology
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
SAVA
10 May 24
in a large population of people with Alzheimer's disease over 12 and 18 months. The target study population is people with mild
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
ADIL
AGEN
AGX
12 Apr 24
maintained Lovesac with a Buy and lowered the price target from $34 to $30.
Applied Digital Corporation
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, NYCB, Amylyx, and InMode and Encourages Investors to Contact the Firm
AMLX
INMD
NYCB
25 Mar 24
. The Company's target customers include dermatologists, dentists, obstetricians and gynecologists, and medical spas. The complaint
oipdro4nnd4kl0plmp
SAVA
25 Mar 24
and function. By targeting altered filamin A, simufilam may help patients with Alzheimer's achieve better health outcomes
to1slhs2gh icivw50shaydpc7nqz2hcs89b5bxzougqmx
AMLX
INMD
NYCB
21 Mar 24
purporting to offer body sculpting and other rejuvenation technologies. The Company's target customers include dermatologists, dentists, obstetricians
- Prev
- 1
- Next